Access the full text.
Sign up today, get DeepDyve free for 14 days.
Duk‐Woo Park, Cheol-Whan Lee, S. Yun, Young-Hak Kim, M. Hong, Jae‐Joong Kim, Seong-Wook Park, Seung‐Jung Park (2007)
Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantationHeart, 93
M. Malaguarnera, M. Vacante, C. Russo, G. Malaguarnera, T. Antić, L. Malaguarnera, R. Bella, G. Pennisi, F. Galvano, A. Frigiola (2012)
Lipoprotein(a) in Cardiovascular DiseasesBioMed Research International, 2013
A. Buffon, G. Liuzzo, L. Biasucci, P. Pasqualetti, V. Ramazzotti, A. Rebuzzi, F. Crea, A. Maseri (1999)
Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty.Journal of the American College of Cardiology, 34 5
A. Farb, G. Sangiorgi, A. Carter, V. Walley, W. Edwards, R. Schwartz, R. Virmani (1999)
Pathology of acute and chronic coronary stenting in humans.Circulation, 99 1
Farooq (2011)
Restenosis: Delineating the numerous causes of drug-eluting stent restenosisCirc Cardiovasc Interv, 4
Thomas Greco, Ann Conti-Kelly, J. Anthony, Thomas Greco, R. Doyle, M. Boisen, Kazuo Kojima, E. Matsuura, Luis Lopez (2010)
Oxidized-LDL/beta(2)-glycoprotein I complexes are associated with disease severity and increased risk for adverse outcomes in patients with acute coronary syndromes.American journal of clinical pathology, 133 5
E. Lev, K. Bliden, Y. Jeong, Shachi Pandya, K. Kang, C. Franzese, U. Tantry, P. Gurbel (2014)
Influence of Race and Sex on Thrombogenicity in a Large Cohort of Coronary Artery Disease PatientsJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 3
H. May, Jeffrey Anderson, Jeffrey Anderson, R. Pearson, J. Jensen, B. Horne, F. Lavasani, H. Yannicelli, J. Muhlestein, J. Muhlestein (2008)
Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).The American journal of cardiology, 101 4
P. Teirstein, V. Massullo, S. Jani, J. Popma, G. Mintz, R. Russo, R. Schatz, E. Guarneri, S. Steuterman, N. Morris, M. Leon, P. Tripuraneni (1997)
Catheter-based radiotherapy to inhibit restenosis after coronary stenting.The New England journal of medicine, 336 24
R. Kornowski, M. Hong, F. Tio, O. Bramwell, Hongsheng Wu, M. Leon (1998)
In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia.Journal of the American College of Cardiology, 31 1
A. Ong, E. Mcfadden, E. Regar, P. Jaegere, R. Domburg, P. Serruys (2005)
Late angiographic stent thrombosis (LAST) events with drug-eluting stents.Journal of the American College of Cardiology, 45 12
C. McNamara, I. Sarembock, B. Bachhuber, G. Stouffer, M. Ragosta, W. Barry, L. Gimple, E. Powers, G. Owens (1996)
Thrombin and Vascular Smooth Muscle Cell Proliferation: Implications for Atherosclerosis and RestenosisSeminars in Thrombosis and Hemostasis, 22
Michael Lee, E. David, R. Makkar, J. Wilentz (2004)
Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation–fibrinolysis systemThe Journal of Pathology, 203
A. Dibra, G. Ndrepepa, J. Mehilli, J. Dirschinger, J. Pache, H. Schühlen, A. Schömig, A. Kastrati (2005)
Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents.The American journal of cardiology, 95 10
W. Kang, Tae Ahn, C. Moon, Seung Han, E. Shin, Jung‐Sun Kim, Y. Ko, D. Choi, Y. Jang, B. Kim, S. Oh, D. Jeon, Joo Yang (2008)
Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stentsHeart, 95
S. Cassese, G. Ndrepepa, Lamin King, T. Tada, M. Fusaro, A. Kastrati (2012)
Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomised trials versus other limus-eluting stents and an adjusted indirect comparisonHeart, 98
R. Erbel, M. Haude, H. Höpp, D. Franzen, H. Rupprecht, B. Heublein, K. Fischer, P. Jaegere, P. Serruys, W. Rutsch, P. Probst (1998)
Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group.The New England journal of medicine, 339 23
S. Miyamoto, H. Kawano, T. Kudoh, H. Soejima, S. Kojima, J. Hokamaki, Hidetomo Maruyoshi, T. Sakamoto, M. Yoshimura, Y. Ozaki, H. Ogawa (2005)
Usefulness of preprocedural platelet aggregation to predict restenosis after percutaneous coronary intervention.The American journal of cardiology, 96 1
R. Waters, D. Kandzari, H. Phillips, Lawrence Crawford, M. Sketch (2005)
Late thrombosis following treatment of in‐stent restenosis with drug‐eluting stents after discontinuation of antiplatelet therapyCatheterization and Cardiovascular Interventions, 65
K. Kulkarni (2006)
Cholesterol profile measurement by vertical auto profile method.Clinics in laboratory medicine, 26 4
Richard Williams (2009)
Cardiovascular disease in African American women: a health care disparities issue.Journal of the National Medical Association, 101 6
K. Udipi, R. Melder, Mingfei Chen, Peiwen Cheng, Ayala Hezi-Yamit, Carol Sullivan, J. Wong, J. Wilcox (2007)
The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 3 1
K. Udipi, Mingfei Chen, Peiwen Cheng, Ke Jiang, D. Judd, A. Cáceres, R. Melder, J. Wilcox (2008)
Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent.Journal of biomedical materials research. Part A, 85 4
K. Toutouzas, A. Colombo, C. Stefanadis (2004)
Inflammation and restenosis after percutaneous coronary interventions.European heart journal, 25 19
P. Toth, M. Davidson (2010)
High-density lipoproteins: marker of cardiovascular risk and therapeutic target.Journal of clinical lipidology, 4 5
E. Angelantonio, P. Gao, L. Pennells, S. Kaptoge, M. Caslake, A. Thompson, A. Butterworth, N. Sarwar, D. Wormser, D. Saleheen, C. Ballantyne, B. Psaty, J. Sundström, P. Ridker, D. Nagel, R. Gillum, I. Ford, P. Ducimetiere, S. Kiechl, W. Koenig, R. Dullaart, G. Assmann, R. D'Agostino, G. Dagenais, J. Cooper, D. Kromhout, A. Onat, R. Tipping, A. Gómez-de-la-Cámara, A. Rosengren, S. Sutherland, J. Gallacher, F. Fowkes, E. Casiglia, A. Hofman, V. Salomaa, E. Barrett-Connor, R. Clarke, E. Brunner, J. Jukema, L. Simons, M. Sandhu, N. Wareham, K. Khaw, J. Kauhanen, J. Salonen, W. Howard, B. Nordestgaard, A. Wood, S. Thompson, S. Boekholdt, N. Sattar, C. Packard, V. Gudnason, J. Danesh (2012)
Lipid-related markers and cardiovascular disease prediction.JAMA, 307 23
F. Schoebel, A. Peters, I. Kreis, F. Gradaus, M. Heins, T. Jax (2008)
Relevance of hemostasis on restenosis in clinically stable patients undergoing elective PTCA.Thrombosis research, 122 2
Tocci (2015)
Blood pressure levels at the time of percutaneous coronary revascularization and risk of coronary in-stent restenosisAm J Hypertens
Duk‐Woo Park, S. Yun, Jong-Young Lee, Won-Jang Kim, Soo-Jin Kang, Seung‐Whan Lee, Young-Hak Kim, Cheol-Whan Lee, Jae‐Joong Kim, Seong-Wook Park, Seung‐Jung Park (2009)
C-Reactive Protein and the Risk of Stent Thrombosis and Cardiovascular Events After Drug-Eluting Stent ImplantationCirculation, 120
B. Chandrasekar, J. Tanguay (2000)
Platelets and restenosis.Journal of the American College of Cardiology, 35 3
Morali Sharma, J. Farmer, A. Garber (2011)
Type 2 diabetes and cardiovascular risk factorsCurrent Medical Research and Opinion, 27
Masanori Taniwaki, G. Stefanini, S. Silber, G. Richardt, P. Vranckx, P. Serruys, P. Buszman, H. Kelbaek, S. Windecker (2014)
4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary InterventionJournal of the American College of Cardiology, 63 16
A. Salvioni, S. Galli, G. Marenzi, G. Lauri, G. Perego, E. Assanelli, M. Guazzi (1998)
Thrombin activation and late restenosis after percutaneous transluminal coronary angioplasty.American heart journal, 135 3
Khosravi (2011)
Does lipoprotein (a) level have a predictive value in restenosis after coronary stentingInt J Prev Med, 2
G. Cvirn, Gerd Hoerl, A. Schlagenhauf, E. Tafeit, M. Brodmann, G. Juergens, M. Koestenberger, T. Gary (2012)
Stent implantation in the superficial femoral artery: short thrombelastometry-derived coagulation times identify patients with late in-stent restenosis.Thrombosis research, 130 3
A. Cai, Liwen Li, Ying Zhang, Y. Mo, Zhi-Gen Li, W. Mai, Ying-ling Zhou (2013)
Baseline LDL-C and Lp(a) Elevations Portend a High Risk of Coronary Revascularization in Patients after Stent PlacementDisease Markers, 35
G. Talarico, F. Burzotta, C. Trani, A. Tommasino, G. Niccoli, I. Porto, A. Leone, R. Mongiardo, G. Schiavoni, F. Crea (2013)
One‐year outcomes of consecutive patients treated by endeavor zotarolimus and resolute zotarolimus stents: The impact of polymer coating in drug‐eluting stent technologyCatheterization and Cardiovascular Interventions, 81
R. Zahn, C. Hamm, S. Schneider, U. Zeymer, G. Richardt, M. Kelm, B. Levenson, T. Bonzel, U. Tebbe, G. Sabin, C. Nienaber, J. Senges (2006)
Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry.American heart journal, 152 6
S. Schulz, D. Sibbing, S. Braun, T. Morath, J. Mehilli, S. Massberg, R. Byrne, A. Schömig, A. Kastrati (2010)
Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents.American heart journal, 160 2
E. Guerra, R. Byrne, A. Kastrati (2014)
Pharmacological inhibition of coronary restenosis: systemic and local approachesExpert Opinion on Pharmacotherapy, 15
Jung-Sun Kim, Myung-Hyun Kim, Byoung‐Kwon Lee, S. Rim, P. Min, Se-Jung Yoon, Jeong-Ho Kim, Ji-Hyuck Rhee, Y. Yoon, B. Hong, H. Kwon, Changsoo Kim (2008)
Effects of increasing particle size of low-density lipoprotein on restenosis after coronary stent implantation.Circulation journal : official journal of the Japanese Circulation Society, 72 7
D. Kandzari, M. Leon, I. Meredith, J. Fajadet, W. Wijns, L. Mauri (2013)
Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.JACC. Cardiovascular interventions, 6 5
D. Kereiakes, T. Linnemeier, D. Baim, R. Kuntz, Charley O’Shaughnessy, J. Hermiller, S. Fink, A. Lansky, Naomi Nishimura, T. Broderick, J. Popma (2000)
Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials).The American journal of cardiology, 86 3
J. Muñoz, J. Alonso, J. Durán, F. Gimeno, B. Ramos, I. Garcimartín, L. Fuente, I. Gómez, F. Fernández‐Avilés (2002)
Coronary stent implantation in patients older than 75 years of age: clinical profile and initial and long-term (3 years) outcome.American heart journal, 143 4
P. Gurbel, K. Bliden, K. Butler, U. Tantry, T. Gesheff, Cheryl Wei, R. Teng, M. Antonino, Shankar Patil, Arun Karunakaran, D. Kereiakes, C. Parris, Drew Purdy, V. Wilson, G. Ledley, R. Storey (2009)
Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET StudyCirculation, 120
Wenhua He, You Zhou, Jin-xin Liu, Jie Liu (2013)
Association of baseline high-density lipoprotein levels with restenosis after coronary stenting: a meta-analysisCoronary Artery Disease, 24
P. Gurbel, K. Bliden, K. Guyer, Peter Cho, K. Zaman, R. Kreutz, A. Bassi, U. Tantry (2005)
Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.Journal of the American College of Cardiology, 46 10
S. Steinhubl, S. Ellis, K. Wolski, A. Lincoff, E. Topol (2001)
Ticlopidine Pretreatment Before Coronary Stenting Is Associated With Sustained Decrease in Adverse Cardiac Events: Data From the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) TrialCirculation: Journal of the American Heart Association, 103
V. Farooq, B. Gogas, P. Serruys (2011)
Contemporary Reviews in Interventional Cardiology Restenosis Delineating the Numerous Causes of Drug-Eluting Stent Restenosis
Background and Objective In‐stent restenosis (ISR) is a limitation of percutaneous coronary intervention and has been linked to specific clinical and angiographic variables. We aimed to simultaneously assess thrombosis biomarkers and lipid levels in patients with and without ISR. Methods Consecutive patients (n = 170) with a history of coronary stenting undergoing elective angiography were studied. Blood samples for thrombelastography, light transmittance aggregometry, and lipid levels were obtained prior to cardiac catheterization. Results Sixty‐nine patients (41%) had ISR (>50% luminal diameter stenosis). Among patients with ISR, 40 (58%) had ISR in more than one stent bed. Patients with ISR were more often female (37.7% vs. 21.8%, P = 0.04), had higher thrombin‐induced platelet‐fibrin clot strength (TIP‐FCS) (69.9 mm vs. 65.6 mm, P < 0.001), and a higher ApoB/A1 ratio (0.65 vs. 0.59, P = 0.03). In patients on dual antiplatelet therapy (n = 86), there were no differences in ADP‐, arachidonic acid‐, and collagen‐induced platelet aggregation between groups. The frequency of patients with ISR increased with TIP‐FCS quartiles and by ROC analysis, TIP‐FCS = 67.0 mm was the cutpoint for identification of ISR (AUC = 0.80 (95%CI 0.73–0.87, P < 0.0001). By multivariate analysis, TIP‐FCS ≥67.0 mm strongly associated with ISR (OR = 7.3, P = 0.004). Conclusion Patients with ISR identified at the time of cardiac catheterization have a prothrombotic phenotype indicated by high TIP‐FCS, a novel marker. Studies to confirm the prognostic utility of high TIP‐FCS for the development of ISR are ongoing. (J Interven Cardiol 2016;29:168–178)
Journal of Interventional Cardiology – Wiley
Published: Apr 1, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.